Bispecific chimeric antigen receptors targeting CD20 and BCMA
US12311022B2 · kind B2 · utility
0Cited by
51References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 27, 2024 |
| Grant date | May 27, 2025 |
| Priority date | — |
| Expiry date | Dec 27, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.